Skip to Content
Merck
  • The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow.

The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow.

General pharmacology (1996-12-01)
S Murakami, Y Ohta, Y Asami, I Yamagishi, Y Toda, M Sato, K Tomisawa
ABSTRACT

1. A novel ACAT (acyl-CoA: cholesterol acyltransferase) inhibitor, HL-004, exhibited a strong inhibitory effect on the hepatic and intestinal ACAT, but was less effective on the adrenal ACAT in vitro. 2. HL-004 selectively decreased serum VLDL cholesterol, and inhibited hepatic ACAT activity in hamsters fed normal chow. 3. These results suggest that the cholesterol-lowering effect of HL-004 can be attributed to a decrease in hepatic VLDL secretion via inhibition of ACAT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
CI 976, >98% (HPLC), solid